A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8189 in Healthy Volunteers and in Schizophrenia Patients
Phase of Trial: Phase I
Latest Information Update: 08 May 2015
Price : $35 *
At a glance
- Drugs MK 8189 (Primary) ; Antipsychotics
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 05 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 23 Apr 2015 Planned End Date changed from 1 May 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
- 23 Apr 2015 Planned primary completion date changed from 1 May 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.